参考文献
|
-
Chan, J. C.,Lee, Y. H.,Liu, C. Y.,Shih, H. H.,Tsay, P. K.,Tang, W. R.(2019).A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy.Journal of Nursing Research,27(6),e51.
連結:
-
邱惠英,林佑樺,王金洲,陳婉宜,張晃智,林孟志(2016)。肺癌化學治療後病人照護需求與相關因素之探討。護理雜誌,63(3),62-72。
連結:
-
張黎露,朱家瑜,姜紹清,許麗珠,黃國埕,周文珊,張美娟,侯秀香(2015)。標靶治療藥品之皮膚毒性預防及照護指引。腫瘤護理雜誌增訂刊,15,47-80。
連結:
-
Aw, D. C.,Tan, E. H.,Chin, T. M.,Lim, H. L.,Lee, H. Y.,Soo, R. A.(2018).Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Asia-Pacific Journal of Clinical Oncology,14(1),23-31.
-
Chren, M. M.(1997).Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin disease.Archives of Dermatology,133,1433-1440.
-
Chren, M. M.,Lasek, R. J.,Quinn, L. M.,Mostow, E. N.,Zyzanski, S. J.(1996).Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness.Journal of Investigative Dermatology,107(5),707-713.
-
Chu, C. Y.,Chen, K. Y.,Chang, J. W. C.,Wei, Y. F.,Lee, C. H.,Wang, W. M.(2017).Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities.Journal of the Formosan Medical Association,116(6),413-423.
-
Donald, P. B.,Digant, G.,Edgar, D. S.(2011).Quality of life assessment as a predictor of survival in non-small cell lung cancer.BMC Cancer,11,353.
-
Fitch, M.(1994).Providing supportive care for individuals living with cancer.Toronto:Ontario Cancer Treatment and Research Foundation.
-
Hirsh, V.(2011).Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer.Current Oncology,18(3),126-138.
-
Joshi, S. S.,Ortiz, S.,Witherspoon, J. N.,Rademaker, A.,West, D. P.,Anderson, R.,Rosenbaum, S. E.,Lacouture, M. E.(2010).Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.Cancer,116(16),3916-3923.
-
Kozuki, T.(2016).Skin problems and EGFR-tyrosine kinase inhibitor.Japanese Journal of Clinical Oncology,46(4),291-298.
-
Lacouture, M. E.,Anadkat, M. J.,Bensadoun, R. J.,Bryce, J.,Chan, A.,Epstein, J. B.,Eaby-Sandy, B.,Murphy, B. A.(2011).Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Supportive Care in Cancer,19(8),1079-1095.
-
Lacouture, M. E.,Anadkat, M.,Jatoi, A.,Garawin, T.,Bohac, C.,Mitchell, E.(2018).Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review.Clinical Colorectal Cancer,17(2),85-96.
-
Lupu, I.,Voiculescu, V. M.,Bacalbasa, N.,Cojocaru, I.,Vrancian, V.,Giurcaneanu, C.(2016).Cutaneous complications of molecular targeted therapy used in oncology.Journal of Medicine and Life,9(1),19.
-
Maguire, R.,Papadopoulou, C.,Kotronoulas, G.,Simpson, M. F.,Mcphelim, J.,Irvine, L.(2013).A systematic review of supportive care needs of people living with lung cancer.European Journal of Oncology Nursing,17(4),449-464.
-
Masago, K.,Imamichi, F.,Masuda, Y.,Ariga, N.,Fujitomi, K.,Fukumine, Y.,Hatakenaka, K.,Fujita, S.,Katakami, N.(2018).Team management of skin rash associated with use of epidermal growth factor receptor-tyrosine kinase inhibitors.Asia-Pacific Journal of Oncology Nursing,5(4),430-434.
-
Melosky, B.,Anderson, H.,Burkes, R. L.,Chu, Q.,Hao, D.,Ho, V.,Ho, C.,Lam, W.,Lee, C. W.,Leighl, N, B.,Murray, N.,Sun, S.,Winston, R.,Laskin, J. J.(2016).Pan canadian rash trial: A randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor- induced skin toxicities in patient with metastatic lung cancer.Journal of Clinical Oncology,34(8),810-815.
-
National Cancer Institutes. (2010). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.3, Retrieved from https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_4.03.xlsx
-
NCCN Clinical Practice Guideline in Oncology. Non- small cell lung cancer (2021, March 29). National Comprehensive Cancer Network.Retrieved from https://www.nccn.org/professionals/ physician_gls/ pdf/nscl.pdf
-
Olver, I.,Keefe, D.,Herrstedt, J.,Warr, D.,Roila, F.,Ripamonti, C.(2020).Supportive care in cancer-a MASCC perspective.Supportive Care in Cancer,28,3467-3475.
-
Pugliese, S. B.,Neal, J. W.,Kwong, B. Y.(2015).Management of dermatologic complications of lung cancer therapies.Current treatment Options in Oncology,16(10),50.
-
Rigdon, A. S.(2010).Development of patient education for older adults receiving chemotherapy.Clinical Journal of Oncology Nursing,14(4),433-441.
-
Rosen, A. C.,Case, E. C.,Dusza, S. W.,Balagula, Y.,Gordon, J.,West, D. P.,Lacouture, M. E.(2013).Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.American jourmal of Clinical Dermatology,14(4),327-333.
-
Tischer, B.,Huber. R.,Kraemer, M.,Lacouture. M. E.(2017).Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.Supportive Care in Cancer,25(2),651-660.
-
Tseng, L. C.,Chen, K. H.,Wang, C. L.,Weng, L. C.(2020).Effects of tyrosine kinaseinhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer.Medicine,99(23),e20510.
-
Velikova, G.,Booth, L.,Smith, A. B.,Brown, P. M.,Lynch, P.,Brown, J. M.,Selby, P. J.(2018).Measuring quality of life in routine oncology practice.Journal of Clinical Oncology,22(4),714-724.
-
柯獻欽,鄭高珍(2018)。晚期非小細胞肺癌之化學治療與標靶治療。內科學誌,29(3),143-152。
-
衛生福利部中央衛生健康保險署(2020,6月1日),藥品給付規定,第九節抗癌瘤藥物。https://www.nhi.gov.tw/Content_List.aspx?n = E70D4F1BD029DC37&topn=3FC7D09599D25979
-
衛生福利部國民健康屬(2021,3月22日),107年癌症登記報告。https://www.hpa.gov.tw/Pages/List.aspx?nodeid=269
-
衛生福利部統計處(2021,6月18日),109年主要癌症死亡統計。https://dep.mohw.gov.tw/dos/cp-1735-3242-113.html
|